Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Pieter LangerhorstSomayya NooriMarina ZajecYolanda B De RijkeJolein GloerichAlain J van GoolHélène CaillonIrma JoostenTheo M LuiderJill CorreMartijn M VanDuijnThomas DejoieJoannes F M JacobsPublished in: Clinical chemistry (2022)
Our data indicate proof-of-principle that MS-MRD evaluation in blood is a feasible, patient friendly alternative to NGS-MRD assessed on bone marrow. Clinical validation of the prognostic value of MS-MRD and its complementary value in MRD-evaluation of patients with MM is warranted in an independent larger cohort.
Keyphrases
- mass spectrometry
- bone marrow
- mesenchymal stem cells
- multiple myeloma
- liquid chromatography
- multiple sclerosis
- ms ms
- gas chromatography
- high performance liquid chromatography
- capillary electrophoresis
- high resolution
- case report
- electronic health record
- copy number
- dna methylation
- loop mediated isothermal amplification
- genome wide
- circulating tumor cells
- clinical evaluation